Oncology Screening Blood Panel for Men (Pakiet Nowotworowy ON)

A thirteen-test screening bundle for men that combines general blood values with a set of tumour markers commonly reviewed in oncology risk assessment — including PSA (prostate), CEA, CA 72-4 and AFP — alongside morphology, OB, glucose, CRP, coagulation (INR, APTT), LDH, calcium and uric acid. Drawn in a single visit and priced as a fixed bundle, it is intended as a broad periodic screen to bring to a doctor, not a standalone diagnosis. Full results take up to nine working days.

neoMedica's "Pakiet Nowotworowy ON" is a broad oncology-oriented screening panel for men that gathers thirteen laboratory tests into one discounted bundle. From a single venous draw it covers general markers — a complete blood count (morfologia), the OB inflammation marker, glucose, CRP, the coagulation parameters INR and APTT, LDH, calcium and uric acid — together with four tumour markers: tPSA (prostate-specific antigen), CEA (carcinoembryonic antigen), CA 72-4 and AFP (alpha-fetoprotein). The purpose of grouping these is to give a wide periodic overview of values that are sometimes elevated in association with various conditions, providing context a physician can weigh alongside symptoms, examination and, where relevant, imaging. It is important to understand what tumour markers can and cannot do: they are screening and monitoring aids that may support a clinical assessment, not a diagnostic test on their own — levels can be raised for benign reasons and can be normal even when something is present, so results are only meaningful when interpreted by a doctor in full context. The panel is sold at a fixed, discounted price of 419 zł and collected in a single appointment at the Świetlana 25 point. Because it includes more specialised assays, neoMedica states the maximum waiting time for the complete set of results is up to nine working days. The package is intended for men who want a broad periodic screen — for instance as part of a wider preventive check — and is best arranged with a follow-up consultation; neoMedica's urology, oncology and internal-medicine services can review the findings and advise whether any value warrants further assessment. As always, the results report laboratory measurements against reference ranges rather than providing a diagnosis.